Stable gastric pentadecapeptide BPC 157 for colitis and multiple sclerosis: Healing of cysteamine‐colitis and colon‐colon‐ anastomosis

Abstract

BPC 157 is interesting as an original anti‐ulcer peptide (GEPPPGKPADDAGLV,M.W. 1419) stable in human gastric juice more than 24 hours, successful in trials for inflammatory bowel disease, phase II, wound treatment, no toxicity or side effects reported, LD1 not achieved, effective alone without carrier. The dehiscence of colonic anastomosis is associated with high mortality and morbidity rates. As a result, the problem of healing after a colon resection requires a suitable solution, especially in inflammatory bowel disease with compromised healing. As a possible solution we suggest the use of BPC 157 which may also be effective for treating inflammatory bowel disease complications. After cysteamine (400 mg/kg ir) colon‐colon anastomosis was created in rats. The sacrifice was at day 3, 5,7, and 14. BPC 157 (10μg/kg, 10 ng/kg) was applied ip once daily or in drinking water (0.16 μg/ml/12ml/day) till the sacrifice. Controls poor presentation did not heal cysteamine colitis and colon‐colon anastomosis; BPC 157 simultaneously induced healing of both, the anastomosis and the ulcerative colitis. Thereby, this evidence advocates BPC 157 in inflammatory bowel disease. Interestingly, accordingly with application of agents used in ulcerative colitis (i.e., natalizumab), the most recent evidence suggests its use also in multiple sclerosis therapy. Supported by Grant 108–1083570‐3635, Croatia